Table 1.
Patient characteristics and CDK 4/6 inhibitor selection per therapy category.
| Therapy category | Patients, n (%) |
Female, n (%) |
Age, mean (range) | Prescribed CDK 4/6 Inhibitor | Patient Count by CDK 4/6 inhibitor |
|---|---|---|---|---|---|
| CDK4/6 monotherapy | 448 (15.4) | 439 (98.0) | 64 (29–100) | Palbociclib | 358 |
| Ribociclib | 28 | ||||
| Abemaciclib | 62 | ||||
| CDK4/6 + hormone therapy | 2050 (70.4) | 2034 (99.2) | 61 (25–99) | Palbociclib | 1752 |
| Ribociclib | 127 | ||||
| Abemaciclib | 171 | ||||
| CDK4/6 + oncolytic agent | 67 (2.3) | 64 (95.5) | 61 (38–84) | Palbociclib | 46 |
| Ribociclib | 5 | ||||
| Abemaciclib | 16 | ||||
| CDK4/6 + another agent + hormone therapy | 341 (11.7) | 337 (98.8) | 60 (29–86) | Palbociclib | 287 |
| Ribociclib | 16 | ||||
| Abemaciclib | 38 | ||||
| Total patients | 2906 (100) | 2874 (98.9) | 61 (25–100) | Palbociclib | 2443 (84.1%) |
| Ribociclib | 176 (6.1%) | ||||
| Abemaciclib | 287 (9.8%) |